PartnershipMay 28, 2026, 09:17 AM
Dyadic & Scripps Research Partner on Hantavirus Vaccine Development
AI Summary
Dyadic International announced a collaboration with Scripps Research to develop rapid-response hantavirus antibody and vaccine candidates, including for the Andes virus. This partnership leverages Dyadic's C1 platform for fast, scalable biologic production, building on prior research into Andes, Marburg, and Ebola viruses. The initiative aims to enhance pandemic preparedness by improving the speed, scalability, and cost-effectiveness of biologic manufacturing, with Dyadic also noting growing commercial activity in non-pharmaceutical applications.
Key Highlights
- Dyadic and Scripps Research partnered for rapid-response hantavirus antibody and vaccine development.
- The collaboration leverages Dyadic's C1 platform for fast, scalable biologic production.
- Focus includes hantaviruses like Andes virus, building on prior Andes, Marburg, and Ebola research.
- Dyadic's C1 platform has shown comparable efficacy to mammalian systems in preclinical studies.
- The company is involved in funded collaborations with the Gates Foundation and CEPI.
- Dyadic and Scripps plan to explore external partnership and non-dilutive funding opportunities.
- Dyadic also highlighted growing commercial activity in non-pharmaceutical protein applications.
Price Impact
More from DYAI